-
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
Tuesday, March 25, 2025 - 2:49pm | 479Read More...Stifel initiated coverage on Monday on Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development...
